Expression of minor histocompatibility antigen, HA-1, in solid tumor cells

Nobuharu Fujii, Akio Hiraki, Kazuma Ikeda, Yasushi Ohmura, Isao Nozaki, Katsuji Shinagawa, Fumihiko Ishimaru, Katsuyuki Kiura, Nobuyoshi Shimizu, Mitsune Tanimoto, Mine Harada

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background. Minor histocompatibility antigen (mHag) induces and mounts graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Among several mHags, HA-1 is one that acts alone and is the most studied. It is suggested that HA-1 may be one of the immunodominant antigens inducing not only graft-versus-host disease but also graft-versusmalignancy effects. There are some reports that mHag HA-1-specific cytotoxic T lymphocytes generated from an HA-1-negative donor can lyse HA-1-positive leukemic cells. However, the tissue distribution of HA-1 has been described as restricted to the cells of the hematopoietic lineage. Methods. We examined the HA-1 expression in peripheral blood mononuclear cells (PBMNC), leukemia/ lymphoma cell lines, solid tumor cell lines, and paired samples of tumor and normal tissues from individual cancer patients by quantitative reverse-transcription polymerase chain reaction. Results. We found that mRNA of HA-1 is expressed in all leukemia/lymphoma cell lines and PBMNC. Most of the leukemia/lymphoma cell lines have the same levels of HA-1 expression as a leukemia/lymphoma cell line, Raji. The expression levels of human PBMNC were 14to 19-fold higher than those of Raji. Among 32 solid tumor cell lines, 7 showed >50% expression levels compared with Raji. Conclusions. HA-1 expression in the mRNA level is higher in cells of hematopoietic origin, but this tissue distribution is not strictly restricted. Some solid tumor cells and tissues express HA-1 gene equal to hematopoietic cells.

Original languageEnglish
Pages (from-to)1137-1141
Number of pages5
JournalTransplantation
Volume73
Issue number7
Publication statusPublished - Apr 15 2002

Fingerprint

Minor Histocompatibility Antigens
Lymphoma
Leukemia
Cell Line
Blood Cells
Graft vs Host Disease
Tissue Distribution
Tumor Cell Line
Neoplasms
Immunodominant Epitopes
Messenger RNA
Hematopoietic Stem Cell Transplantation
Cytotoxic T-Lymphocytes
Cell Lineage
Reverse Transcription
Tissue Donors
Transplants
Polymerase Chain Reaction
Genes

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Fujii, N., Hiraki, A., Ikeda, K., Ohmura, Y., Nozaki, I., Shinagawa, K., ... Harada, M. (2002). Expression of minor histocompatibility antigen, HA-1, in solid tumor cells. Transplantation, 73(7), 1137-1141.

Expression of minor histocompatibility antigen, HA-1, in solid tumor cells. / Fujii, Nobuharu; Hiraki, Akio; Ikeda, Kazuma; Ohmura, Yasushi; Nozaki, Isao; Shinagawa, Katsuji; Ishimaru, Fumihiko; Kiura, Katsuyuki; Shimizu, Nobuyoshi; Tanimoto, Mitsune; Harada, Mine.

In: Transplantation, Vol. 73, No. 7, 15.04.2002, p. 1137-1141.

Research output: Contribution to journalArticle

Fujii, N, Hiraki, A, Ikeda, K, Ohmura, Y, Nozaki, I, Shinagawa, K, Ishimaru, F, Kiura, K, Shimizu, N, Tanimoto, M & Harada, M 2002, 'Expression of minor histocompatibility antigen, HA-1, in solid tumor cells', Transplantation, vol. 73, no. 7, pp. 1137-1141.
Fujii N, Hiraki A, Ikeda K, Ohmura Y, Nozaki I, Shinagawa K et al. Expression of minor histocompatibility antigen, HA-1, in solid tumor cells. Transplantation. 2002 Apr 15;73(7):1137-1141.
Fujii, Nobuharu ; Hiraki, Akio ; Ikeda, Kazuma ; Ohmura, Yasushi ; Nozaki, Isao ; Shinagawa, Katsuji ; Ishimaru, Fumihiko ; Kiura, Katsuyuki ; Shimizu, Nobuyoshi ; Tanimoto, Mitsune ; Harada, Mine. / Expression of minor histocompatibility antigen, HA-1, in solid tumor cells. In: Transplantation. 2002 ; Vol. 73, No. 7. pp. 1137-1141.
@article{ecf38e20ef114b8b8c5a126bd760d49c,
title = "Expression of minor histocompatibility antigen, HA-1, in solid tumor cells",
abstract = "Background. Minor histocompatibility antigen (mHag) induces and mounts graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Among several mHags, HA-1 is one that acts alone and is the most studied. It is suggested that HA-1 may be one of the immunodominant antigens inducing not only graft-versus-host disease but also graft-versusmalignancy effects. There are some reports that mHag HA-1-specific cytotoxic T lymphocytes generated from an HA-1-negative donor can lyse HA-1-positive leukemic cells. However, the tissue distribution of HA-1 has been described as restricted to the cells of the hematopoietic lineage. Methods. We examined the HA-1 expression in peripheral blood mononuclear cells (PBMNC), leukemia/ lymphoma cell lines, solid tumor cell lines, and paired samples of tumor and normal tissues from individual cancer patients by quantitative reverse-transcription polymerase chain reaction. Results. We found that mRNA of HA-1 is expressed in all leukemia/lymphoma cell lines and PBMNC. Most of the leukemia/lymphoma cell lines have the same levels of HA-1 expression as a leukemia/lymphoma cell line, Raji. The expression levels of human PBMNC were 14to 19-fold higher than those of Raji. Among 32 solid tumor cell lines, 7 showed >50{\%} expression levels compared with Raji. Conclusions. HA-1 expression in the mRNA level is higher in cells of hematopoietic origin, but this tissue distribution is not strictly restricted. Some solid tumor cells and tissues express HA-1 gene equal to hematopoietic cells.",
author = "Nobuharu Fujii and Akio Hiraki and Kazuma Ikeda and Yasushi Ohmura and Isao Nozaki and Katsuji Shinagawa and Fumihiko Ishimaru and Katsuyuki Kiura and Nobuyoshi Shimizu and Mitsune Tanimoto and Mine Harada",
year = "2002",
month = "4",
day = "15",
language = "English",
volume = "73",
pages = "1137--1141",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Expression of minor histocompatibility antigen, HA-1, in solid tumor cells

AU - Fujii, Nobuharu

AU - Hiraki, Akio

AU - Ikeda, Kazuma

AU - Ohmura, Yasushi

AU - Nozaki, Isao

AU - Shinagawa, Katsuji

AU - Ishimaru, Fumihiko

AU - Kiura, Katsuyuki

AU - Shimizu, Nobuyoshi

AU - Tanimoto, Mitsune

AU - Harada, Mine

PY - 2002/4/15

Y1 - 2002/4/15

N2 - Background. Minor histocompatibility antigen (mHag) induces and mounts graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Among several mHags, HA-1 is one that acts alone and is the most studied. It is suggested that HA-1 may be one of the immunodominant antigens inducing not only graft-versus-host disease but also graft-versusmalignancy effects. There are some reports that mHag HA-1-specific cytotoxic T lymphocytes generated from an HA-1-negative donor can lyse HA-1-positive leukemic cells. However, the tissue distribution of HA-1 has been described as restricted to the cells of the hematopoietic lineage. Methods. We examined the HA-1 expression in peripheral blood mononuclear cells (PBMNC), leukemia/ lymphoma cell lines, solid tumor cell lines, and paired samples of tumor and normal tissues from individual cancer patients by quantitative reverse-transcription polymerase chain reaction. Results. We found that mRNA of HA-1 is expressed in all leukemia/lymphoma cell lines and PBMNC. Most of the leukemia/lymphoma cell lines have the same levels of HA-1 expression as a leukemia/lymphoma cell line, Raji. The expression levels of human PBMNC were 14to 19-fold higher than those of Raji. Among 32 solid tumor cell lines, 7 showed >50% expression levels compared with Raji. Conclusions. HA-1 expression in the mRNA level is higher in cells of hematopoietic origin, but this tissue distribution is not strictly restricted. Some solid tumor cells and tissues express HA-1 gene equal to hematopoietic cells.

AB - Background. Minor histocompatibility antigen (mHag) induces and mounts graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Among several mHags, HA-1 is one that acts alone and is the most studied. It is suggested that HA-1 may be one of the immunodominant antigens inducing not only graft-versus-host disease but also graft-versusmalignancy effects. There are some reports that mHag HA-1-specific cytotoxic T lymphocytes generated from an HA-1-negative donor can lyse HA-1-positive leukemic cells. However, the tissue distribution of HA-1 has been described as restricted to the cells of the hematopoietic lineage. Methods. We examined the HA-1 expression in peripheral blood mononuclear cells (PBMNC), leukemia/ lymphoma cell lines, solid tumor cell lines, and paired samples of tumor and normal tissues from individual cancer patients by quantitative reverse-transcription polymerase chain reaction. Results. We found that mRNA of HA-1 is expressed in all leukemia/lymphoma cell lines and PBMNC. Most of the leukemia/lymphoma cell lines have the same levels of HA-1 expression as a leukemia/lymphoma cell line, Raji. The expression levels of human PBMNC were 14to 19-fold higher than those of Raji. Among 32 solid tumor cell lines, 7 showed >50% expression levels compared with Raji. Conclusions. HA-1 expression in the mRNA level is higher in cells of hematopoietic origin, but this tissue distribution is not strictly restricted. Some solid tumor cells and tissues express HA-1 gene equal to hematopoietic cells.

UR - http://www.scopus.com/inward/record.url?scp=0037091033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037091033&partnerID=8YFLogxK

M3 - Article

C2 - 11965046

AN - SCOPUS:0037091033

VL - 73

SP - 1137

EP - 1141

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 7

ER -